Protagonist Therapeutics, Inc.
PTGX
Peringkat dalam Saham
#2280
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Harga Saham
$136.61
Kapitalisasi Pasar
$8.84B
Perubahan (1 hari)
1.61%
Perubahan (1 tahun)
78.06%
Negara
US
Perdagangan Protagonist Therapeutics, Inc. (PTGX)
Kategori
Healthcare
Riwayat hasil dividen untuk Protagonist Therapeutics, Inc. (PTGX)
Hasil dividen (TTM) dari Protagonist Therapeutics, Inc. (simbol saham: PTGX) per 2023-12-31: 0.00%
Rata-rata hasil dividen selama 5 tahun terakhir: 0.00%
Rata-rata hasil dividen selama 5 tahun terakhir: 0.00%
Riwayat hasil dividen untuk Protagonist Therapeutics, Inc. (PTGX) dari 2014 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
| Tahun | Hasil Dividen | Mengubah |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
Hasil dividen (TTM) untuk perusahaan serupa atau pesaing
| Perusahaan | Hasil Dividen | Negara |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
